Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.30 |
| ▸ | GAPDH | P04406 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083819 | 1.00 | ADH1B (0.34) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL9031315 | 1.00 | ADH1B (0.34) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL12083670 | 1.00 | ADH1B (0.34) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4136407 | 1.00 | ADH1B (0.34) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL9031307 | 1.00 | ADH1B (0.34) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL9865913 | 1.00 | ADH1B (0.34) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL19385831 | 0.98 | CA2 (0.34) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL8993618 | 0.94 | CA2 (0.38) | CA2TSHRCTSK | |
| SCHEMBL14762701 | 0.89 | TRPV1 (0.44) | TSHRFAAHTRPV1MAPT | |
| SCHEMBL14762702 | 0.89 | TRPV1 (0.44) | TSHRFAAHTRPV1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431726-B2 | Preparation method of (3S,4S)-3-hexyl-4-((R)-2-hydroxytridecyl)-oxetan-2-one and the product of that method | Chongqing Zhien Pharmaceutical Co., Ltd. | 2013-04-30 | — | — | US | disclosed |
| US-8258321-B2 | Beta-lactone compounds | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258321-B2 | Beta-lactone compounds | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110046400-A1 | PREPARATION METHOD OF (3S,4S)-3-HEXYL-4-((R)-2-HYDROXYTRIDECYL)-OXETAN-2-0NE AND THE PRODUCT OF THAT METHOD | Chongqing Zhien Pharmaceutical Co., Ltd. (CN) | 2011-02-24 | — | — | US | disclosed |
| US-20090124681-A1 | BETA-LACTONE COMPOUNDS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124681-A1 | BETA-LACTONE COMPOUNDS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-14 | — | — | US | disclosed |
| EP-0444482-B1 | Oxetanones | HOFFMANN LA ROCHE (CH) | 1996-01-17 | — | — | EP | disclosed |
| US-5466708-A | Carbamyloxyoxetanone compounds | HOFFMANN-LA ROCHE INC. (US) | 1995-11-14 | — | — | US | disclosed |
| US-5376674-A | Lipase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5260310-A | Oxetanone compounds and pharmaceutical compositions containing them | HOFFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0444482-A2 | Oxetanones | F. HOFFMANN-LA ROCHE AG (CH) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124681-A1 | BETA-LACTONE COMPOUNDS | LBR, CYP8B1, GLB1 | ADH1B 271/4885ADH1C 180/4885ADH1A 210/4885 |
| US-20110046400-A1 | PREPARATION METHOD OF (3S,4S)-3-HEXYL-4-((R)-2-HYDROXYTRIDECYL)-OXETAN-2-0NE AND THE PRODUCT OF THAT METHOD | LANCL2, HAO2, HACL2 | ADH1B 337/4885ADH1C 42/4885ADH1A 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.